Search results
Results from the WOW.Com Content Network
Acarbose is an oligosaccharide, whereas miglitol resembles a monosaccharide. Miglitol is fairly well absorbed by the body, as opposed to acarbose. Moreover, acarbose inhibits pancreatic alpha-amylase in addition to alpha-glucosidase, and is degraded by gut bacterial maltogenic alpha-amylase and cyclomaltodextrinase. [4] [5]
Miglitol is an oral alpha-glucosidase inhibitor used in the treatment of type 2 diabetes. It works by reversibly inhibiting alpha-glucosidase enzymes in the small intestine, which delays the digestion of complex carbohydrates and subsequently reduces postprandial glucose levels. [ 1 ]
Acarbose degradation is the unique feature of glycoside hydrolases in gut microbiota, acarbose degrading glucosidase, which hydrolyze acarbose into an acarviosine-glucose and glucose. [17] Human enzymes do transform acarbose: the pancreatic alpha-amylase is able to perform a rearrangement reaction , moving the glucose unit in the "tail" maltose ...
The absorption rate constant K a is a value used in pharmacokinetics to describe the rate at which a drug enters into the system. It is expressed in units of time −1. [1] The K a is related to the absorption half-life (t 1/2a) per the following equation: K a = ln(2) / t 1/2a. [1] K a values can typically only be found in research articles. [2]
Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. [ 2 ] There are three major drugs which belong to this class, acarbose , miglitol and voglibose, [ 2 ] of which voglibose is the newest.
Alpha-glucosidase inhibitors (acarbose, miglitol, voglibose) Inhibit carbohydrate digestion in the small intestine by inhibiting enzymes that break down polysaccharides Slightly lower risk of hypoglycemia compared to sulfonylureas; Associated with modest weight loss; Decreases triglycerides; No detrimental effect on cholesterol
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.